Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma

BACKGROUND: Anaplastic thyroid cancer (ATC) is considered the most lethal thyroid cancer, with an overall 5‐year survival rate below 10%. The FDA approved a BRAF/MEK inhibitor combination for the treatment of patients with BRAF‐mutated ATC. However, effective therapeutic options for patients with wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shuwen, Ji, Dongmei, Xue, Fen, Chen, Tongzhen, Wang, Yu, Ji, Qinhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875607/
https://www.ncbi.nlm.nih.gov/pubmed/36535914
http://dx.doi.org/10.1002/cnr2.1770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875607/
https://www.ncbi.nlm.nih.gov/pubmed/36535914
http://dx.doi.org/10.1002/cnr2.1770

Ejemplares similares